During the development of a new drug, which would be included in the study by the researcher to prevent any bias or unrealistic expectations of the new drug's usefulness?
a. a placebo
b. fda approval
c. informal consent
d. efficacy information

Option-A

Explanation:

In the given question, since the examiner has mentioned the time that the factor the researcher should include during the development of a new drug is "the placebo". A placebo is used during the experiment as control by and its effect depend on the expectations of the patient since the placebo does not contain the active drugs.

The FDA approval, informed consent and the information are not used until the study is going on.

Thus, Option-A is the correct answer.

there are mainly three domains in biological classification namely; archaea, bacteria, and eukarya.

archaea includes all the prokaryotic cells which are characterized by their lipid membranes. they have branched hydrocarbon which is attached to glycerol through an ether linkage.

bacteria includes all the prokaryotic cells, the cell membrane of which are made up of the unbranched fatty acid chain. in addition, they are attached to glycerol through an ester bond.

eukarya includes all the eukaryotic cells, that is, the cells contain a nucleus and other membrane-bound cell organelles.

they can be autotrophic as well as heterotrophic, unicellular as well as multicellular

they include kingdoms like protista, plantae, animalia, fungi et cetera.

read more on -

explanation:

i think its white blood cells

i hope this